In The Media

Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale

How NurExone Biologic Advances Regenerative Nanodrugs for CNS Injuries Led by Dr. Lior Shaltiel

NurExone: Finanzzahlen und Meilensteine markieren den Start ins Jahr 2026

לגדל חוט שדרה: הסטארט-אפ מחיפה שרוצה לגרום למשותקים לחזור ללכת

EXCLUSIVE: NurExone Targets Mexico Wellness Market With Exosome Supply Agreement

From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair

Emerging Modalities - Laying the Groundwork for Clinical and Regulatory Success

How NurExone Biologic is Shaping the Future of Regenerative Therapies

Developing Exosome-Based RNA Therapeutics For CNS Regeneration

Exosome Exotherapy: Lior Shaltiel on a Platform for CNS Regeneration